Loading
NASDAQHealthcareMedical - Care Facilities
Latest quote
$0.379
+$0.0355 · +10.33%
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Latest quote
$0.379
+$0.0355 · +10.33%
After-hours
$0.3701
−$0.0089 · -2.35%
Oct 8, 6:12 PM ET
Regular session · ET · Market data may be delayed.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Day range
Current $0.379
52-week range
Current $0.379
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
58
Mixed
Risk
79
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Day range
Current $0.379
52-week range
Current $0.379
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.05M USD | 1.75M USD | 1.42M USD | 11.06M USD | 9.62M USD |
| Cost of goods sold | 1.44M USD | 1.39M USD | 1.32M USD | 5.94M USD | 4.93M USD |
| Gross profit | 604.54K USD | 360.31K USD | 109.14K USD | 5.12M USD | 4.69M USD |
| Research and development | 592.57K USD | 1.26M USD | 1.41M USD | 120.04K USD | 193.37K USD |
| Selling, general, and administrative | 3.34M USD | 4.76M USD | 5.06M USD | 3.32M USD | 2.56M USD |
| Operating expenses | 3.94M USD | 6.02M USD | 6.47M USD | 3.44M USD | 2.75M USD |
| Interest income | 21.4K USD | 79.47K USD | 209.15K USD | 68.42K USD | 2.99K USD |
| Interest expense | 156.21K USD | 12.65K USD | 27.92K USD | 15.69K USD | 12.93K USD |
| Depreciation and amortization | 77.98K USD | 135.76K USD | 167.29K USD | 288.69K USD | 123.66K USD |
| Operating income | −3.33M USD | −5.66M USD | −6.36M USD | 1.68M USD | 1.94M USD |
| Net income | −3.74M USD | −5.55M USD | −6.39M USD | 2.19M USD | 2.07M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
1219.26% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
